Michael Triplett

Dr. Michael Triplett is co-founder, President, and CEO of Armatus Bio, Inc., a gene therapy

company based in Columbus, Ohio developing next generation precision therapies for

genetically driven neuromuscular diseases, and Neucore Bio, Inc., a gene therapy company

developing next generation nonviral precision therapeutics for genetically driven neurological

diseases. Dr. Triplett is co-founder and board co-Chair of Clarametyx Biosciences, Inc., a

preclinical infectious disease company pursuing paradigm shifting therapeutics and vaccines for

the treatment and prevention of bacterial biofilm mediated diseases, after serving as founding

President and CEO. Dr. Triplett co-founded and served as President and CEO of Myonexus

Therapeutics, a clinical stage gene therapy company developing first-ever treatments for limb-

girdle muscular dystrophies that Sarepta Therapeutics acquired in 2019.

Dr. Triplett began his career at Procter & Gamble as a Product Development Engineer prior to

attending graduate school. After completing his graduate work in lipid nanoparticle engineering,

he joined Battelle where he held roles of progressing responsibility, spanning business

development, innovation, new venture development, and strategy.

Dr. Triplett serves on several boards, including Andelyn Biosciences, the InnovateOhio Advisory

Board for the DeWine-Husted administration, the Ohio Federal Research Network Executive

Review Board, the Ohio Life Sciences Association where he is Chair, and the Ohio Gene and

Cell Therapy Council where he is co-Chair. He also serves as a Venture Advisor to the Ohio

Innovation Fund, a Columbus, Ohio based venture capital fund. Dr. Triplett is a Founding Partner

of Carmen Ventures, an emerging venture capital fund created by Ohio State University alumni

with the mission of investing in Ohio State University alumni led and IP based ventures.